<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>BioWorld</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Regulatory actions for April 7, 2026</title>
      <description>
        <![CDATA[Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Allevion, Regeneron, Stereotaxis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730145</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730145-regulatory-actions-for-april-7-2026</link>
    </item>
    <item>
      <title>Other news to note for April 7, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Bioinsights, Denali, Immunitybio, Inspira, Nano Dimension, NEC Bio, Profusa, Takeda, Transgene.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730144</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730144-other-news-to-note-for-april-7-2026</link>
    </item>
    <item>
      <title>In the clinic for April 7, 2026</title>
      <description>
        <![CDATA[Clinical updates for biopharma and med tech, including data readouts and publications: Alar, Amgen, Praxis, Vedanta.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730143</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730143-in-the-clinic-for-april-7-2026</link>
    </item>
    <item>
      <title>Financings for April 7, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Acurion, Beacon, Innocan, Opus, OS Therapies, Sharp, Syneron.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730142</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730142-financings-for-april-7-2026</link>
    </item>
    <item>
      <title>Appointments and advancements for April 7, 2026</title>
      <description>
        <![CDATA[New hires and promotions in the biopharma and med-tech industries, including: Avalyn, Biocryst.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730141</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730141-appointments-and-advancements-for-april-7-2026</link>
    </item>
    <item>
      <title>VC activity drives March med-tech financings to $2.4B</title>
      <description>
        <![CDATA[Total med-tech financings reached $8.54 billion in the first quarter (Q1) of 2026, reflecting a modest pullback from $9.33 billion in the same period of 2025 but remaining well above previous years. The Q1 2026 total exceeds the $6.45 billion recorded in Q1 2024 and $4.69 billion in Q1 2023, signaling continued recovery from the post-2021 downturn.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730138</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730138-vc-activity-drives-march-med-tech-financings-to-24b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-arrows-smartphone.webp?t=1768508815" type="image/jpeg" medium="image" fileSize="432030">
        <media:title type="plain">Hand holding smartphone with dollar sign, arrows hovering</media:title>
      </media:content>
    </item>
    <item>
      <title>South Korea streamlines biosimilar review, clinical trials</title>
      <description>
        <![CDATA[South Korea is rolling out regulatory changes to speed biosimilar development, including reforms to shorten review timelines, ease phase III trial requirements and simplify oversight of manufacturing changes.&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/730137</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730137-south-korea-streamlines-biosimilar-review-clinical-trials</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-vials.webp?t=1588350331" type="image/png" medium="image" fileSize="310068">
        <media:title type="plain">Drug vials and syringe</media:title>
      </media:content>
    </item>
    <item>
      <title>Sononeu wins $5.2M ARPA-H grant for ultrasound-activated therapeutics</title>
      <description>
        <![CDATA[Newco Sononeu Inc. has launched to translate more than a decade of basic research in controlling cells with ultrasound into novel, non-invasive therapies for conditions including peripheral and diabetic neuropathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730136</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730136-sononeu-wins-52m-arpa-h-grant-for-ultrasound-activated-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Foot-neuropathy-illustration.webp?t=1775587782" type="image/jpeg" medium="image" fileSize="740144">
        <media:title type="plain">Neuropathy illustrated in legs and feet</media:title>
      </media:content>
    </item>
    <item>
      <title>Kennedy sidestepping court order sidelining ACIP?</title>
      <description>
        <![CDATA[Don’t like a court order? Sidestep it. That seems to be the idea behind U.S. Health and Human Services Secretary Robert Kennedy’s latest changes to his renewal of the charter for the CDC’s Advisory Committee on Immunization Practices (ACIP).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730135</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730135-kennedy-sidestepping-court-order-sidelining-acip</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Businessman-signing-documents.webp?t=1738961282" type="image/jpeg" medium="image" fileSize="120407">
        <media:title type="plain">Businessman signing documents</media:title>
      </media:content>
    </item>
    <item>
      <title>Amplia halts enrollment in phase II pancreatic cancer trial </title>
      <description>
        <![CDATA[Amplia Therapeutics Ltd. has halted recruitment in its phase II Amplicity trial in advanced pancreatic cancer due to three dose-limiting toxicities related to the chemotherapy regimen, modified FOLFIRINOX (mFOLFIRINOX), which is being administered in combination with lead compound narmafotinib (AMP-945), a focal adhesion kinase inhibitor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730134</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730134-amplia-halts-enrollment-in-phase-ii-pancreatic-cancer-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/pancreatic-cancer-pancreas-3D.webp?t=1729610305" type="image/jpeg" medium="image" fileSize="283423">
        <media:title type="plain">Illustration of cancer in the pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>Gilead buying Tubulis and its ADCs in $5B takeover bid</title>
      <description>
        <![CDATA[German company Tubulis GmbH, which emerged with a $12.3 million series A round and a next-generation antibody-drug conjugate (ADC) platform about six years ago, has commanded up to $5 billion in a buyout offer from Gilead Sciences Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730133</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730133-gilead-buying-tubulis-and-its-adcs-in-5b-takeover-bid</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/ADC-illustration.webp?t=1763043550" type="image/jpeg" medium="image" fileSize="320648">
        <media:title type="plain">Antibody-drug conjugates floating on light purple background</media:title>
      </media:content>
    </item>
    <item>
      <title>Best of BioWorld: Q1</title>
      <description>
        <![CDATA[A selection of top news from January through March 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730121</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730121-best-of-bioworld-q1</link>
    </item>
    <item>
      <title>Today's news in brief</title>
      <description>
        <![CDATA[BioWorld briefs for April 7, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432891</guid>
      <pubDate>Tue, 07 Apr 2026 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/432891-todays-news-in-brief</link>
    </item>
    <item>
      <title>Regulatory actions for April 6, 2026</title>
      <description>
        <![CDATA[Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Cocrystal, Context, Fore, Eli Lilly, Merck, Ultragenyx, Zeto.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730131</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730131-regulatory-actions-for-april-6-2026</link>
    </item>
    <item>
      <title>Other news to note for April 6, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Adagene, Axsome, Boston Scientific, BSM, Ellipsys, Gilead, Incyte, Lupin, Oncotelics, Phil, Shionogi, Takeda, Tanabe, Techforce, Tenpoint, Valencia, Visufarma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730130</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730130-other-news-to-note-for-april-6-2026</link>
    </item>
    <item>
      <title>In the clinic for April 6, 2026</title>
      <description>
        <![CDATA[Clinical updates for biopharma and med tech, including data readouts and publications: Adagene, Alto Neuroscience, Astrazeneca, Beam, Immunovant, Lipocine, Neutrolis, Novo Nordisk, Pangia, Puretech, Seaport, Soligenix, Vascarta.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730129</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730129-in-the-clinic-for-april-6-2026</link>
    </item>
    <item>
      <title>Financings for April 6, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Adagene, Arch Biopartners, Celldex, Entera, Hoth, Inovio, Stairmed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730128</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730128-financings-for-april-6-2026</link>
    </item>
    <item>
      <title>Appointments and advancements for April 6, 2026</title>
      <description>
        <![CDATA[New hires and promotions in the biopharma and med-tech industries, including: Akebia, Clarametyx, Coya, Curve, Harmony, Royal, Orionis, Pavmed, Telix.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730127</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730127-appointments-and-advancements-for-april-6-2026</link>
    </item>
    <item>
      <title>Stipple launches with $100M for novel oncology targets</title>
      <description>
        <![CDATA[Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s Pointillist discovery platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730120</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730120-stipple-launches-with-100m-for-novel-oncology-targets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-in-light-bulb-on-yellow-background.webp?t=1637008317" type="image/png" medium="image" fileSize="77494">
        <media:title type="plain">Dollar sign in light bulb on yellow background</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma financings nearly double vs. 2025 to $25.1B</title>
      <description>
        <![CDATA[Total biopharma financings reached $25.14 billion in the first quarter (Q1) of 2026, nearly doubling the $13.12 billion in the Q1 2025. The early 2026 total comes in above the $13.19 billion recorded in 2023 and $13.66 billion in 2022, though it remains below the $38.27 billion during the same period in 2021 and $47.25 billion in 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730119</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730119-biopharma-financings-nearly-double-vs-2025-to-251b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gray-and-green-glass-dollar-symbols-with-arrow-pointing-up.webp?t=1731016850" type="image/jpeg" medium="image" fileSize="116588">
        <media:title type="plain">Gray and green glass dollar symbols with arrow pointing up</media:title>
      </media:content>
    </item>
    <item>
      <title>One-carbon has new approach to starving tumors of nucleotides</title>
      <description>
        <![CDATA[Swedish startup One-carbon Therapeutics AB is going after solid tumors with an approach that looks similar to synthetic lethals to some people, and to chemotherapy to others. But One-carbon CEO Ana Slipicevic said that TH-9619, the company’s first-in-class inhibitor of the enzyme MTHFD1/2, is neither of those things.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730118</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730118-one-carbon-has-new-approach-to-starving-tumors-of-nucleotides</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Blue-cancer-cell.webp?t=1753195222" type="image/jpeg" medium="image" fileSize="246736">
        <media:title type="plain">Blue cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Circuit split forming over state 340B laws </title>
      <description>
        <![CDATA[Do state laws requiring drug companies to give steep 340B drug discounts to an unlimited number of contract pharmacies, with no claims data required, interfere with a longstanding contract between the U.S. Congress and biopharma? Or do such laws merely flex states’ authority over pharmacy practices such as delivery?]]>
      </description>
      <guid>http://www.bioworld.com/articles/730117</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730117-circuit-split-forming-over-state-340b-laws</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Gavel-and-medication.webp?t=1614287344" type="image/png" medium="image" fileSize="303099">
        <media:title type="plain">Gavel and pill blister packs</media:title>
      </media:content>
    </item>
    <item>
      <title>Sector tariff now more than a threat – for some Rx companies</title>
      <description>
        <![CDATA[After nearly a year of threats and promises of a global biopharma tariff of 25% to 500%, U.S. President Donald Trump finally delivered it. In the name of national security, he imposed a 100% sector tariff on prescription drugs and their associated ingredients beginning in about four months for large manufacturers and six months for smaller companies. However, depending on the drug, where it’s made and whether a manufacturer has reached onshoring and pricing agreements with the Department of Health and Human Services, the actual tariff could be as low as 0%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730116</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730116-sector-tariff-now-more-than-a-threat-for-some-rx-companies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Tariff-trade-illustration.webp?t=1746219221" type="image/jpeg" medium="image" fileSize="370006">
        <media:title type="plain">Digital globe illustrating pharma trade, tariffs</media:title>
      </media:content>
    </item>
    <item>
      <title>Vykat caveat: Neurocrine’s $2.9B Soleno bid low-ball? </title>
      <description>
        <![CDATA[A proposal to buy out Soleno Therapeutics Inc. didn’t wait for European approval of Vykat XR (diazoxide choline) to treat hyperphagia in Prader-Willi syndrome, as Neurocrine Biosciences Inc. is putting on the table $53 per share in cash, which equates to an equity value of $2.9 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730115</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730115-vykat-caveat-neurocrines-29b-soleno-bid-low-ball</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Vykat-XR.webp?t=1743084103" type="image/jpeg" medium="image" fileSize="92748">
        <media:title type="plain">Vykat XR</media:title>
        <media:description type="plain">Credit: Soleno Therapeutics Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Neurocrine bids $2.9B for Soleno with Vykat in PWS</title>
      <description>
        <![CDATA[A preview of the next edition of BioWorld, April 6, 2026]]>
      </description>
      <guid>http://www.bioworld.com/articles/730132</guid>
      <pubDate>Mon, 06 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730132-neurocrine-bids-29b-for-soleno-with-vykat-in-pws</link>
    </item>
    <item>
      <title>Biggest gainers and losers for March 30-April 3, 2026</title>
      <description>
        <![CDATA[The top 10 biopharma stock gainers and losers for the week.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730125</guid>
      <pubDate>Mon, 06 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730125-biggest-gainers-and-losers-for-march-30-april-3-2026</link>
    </item>
    <item>
      <title>ICYMI: Week in review, March 30-April 3, 2026</title>
      <description>
        <![CDATA[A quick look back at top stories.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730124</guid>
      <pubDate>Mon, 06 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730124-icymi-week-in-review-march-30-april-3-2026</link>
    </item>
    <item>
      <title>Holiday notice</title>
      <description>
        <![CDATA[<em>BioWorld</em>'s offices were closed in observance of Good Friday. No issue was published April 3.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730123</guid>
      <pubDate>Mon, 06 Apr 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730123-holiday-notice</link>
    </item>
    <item>
      <title>BioWorld and Nasdaq stock indices</title>
      <description>
        <![CDATA[These graphs compare the performance of the biotech stocks for all of 2026 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730184</guid>
      <pubDate>Thu, 02 Apr 2026 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730184-bioworld-and-nasdaq-stock-indices</link>
    </item>
    <item>
      <title>Biopharma money raised: Jan. 1-April 2, 2026</title>
      <description>
        <![CDATA[Year-to-date money raised in public, private and other financings of biopharma companies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730182</guid>
      <pubDate>Thu, 02 Apr 2026 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730182-biopharma-money-raised-jan-1-april-2-2026</link>
    </item>
  </channel>
</rss>
